← All trials
NCT07225543
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2026
- Primary completion
- Jul 31, 2030
- Completion date
- Jul 31, 2030
- First posted
- Nov 6, 2025
- Last posted
- Nov 10, 2025
- Enrollment
- 42
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- Vanderbilt UniversityOfficial
- Vanderbilt UniversitySponsor investigator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.